17 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
customary closing conditions.
The Company announced its inclusion on the Dow Jones Sustainability World Index (DJSI World) for the fifth consecutive … year, alongside its fourth consecutive inclusion on the Dow Jones Sustainability North America Index (DJSI North America).
Select Upcoming 2024
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
and Engineering Fair Environmental sustainability Pipeline innovation Access to medicine and fair pricing Patient advocacy Our mission: Use the power
DEFA14A
REGN
Regeneron Pharmaceuticals, Inc.
17 May 23
Additional proxy soliciting materials
4:04pm
shareholder engagement program; and
Regeneron’s strong commitment to both long-term sustainability and shareholder value creation.
Board Leadership
8-K
EX-10.1
xrlyxu7i
20 Dec 22
Entry into a Material Definitive Agreement
4:01pm
DEFA14A
0kwj53 ul
23 Apr 21
Additional proxy soliciting materials
4:21pm
DEFA14A
suhwq
24 Apr 20
Additional proxy soliciting materials
4:14pm
DEFA14A
y1ifzl8qtx38so6 9s
26 Apr 19
Additional proxy soliciting materials
4:08pm
8-K
EX-99.1
vu4gkly
5 Dec 11
Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity
12:00am
8-K
EX-99
rrowgd
6 Feb 07
Entry into a Material Definitive Agreement
12:00am
- Prev
- 1
- Next